Closing Bell Overtime: CRISPR Therapeutics CEO On Milestone FDA Approval; Rick Caruso On Potential Macy’s Sale 12/11/23
Major averages notched their third straight positive session. Wells Fargo’s Scott Wren and CFRA’s Sam Stovall break down the market action. Jefferies analyst Brent Thill breaks down Oracle’s revenue miss. Caruso Founder Rick Caruso talks rumors of a Macy’s sale and the broader state of commercial real estate. CRISPR Therapeutics CEO Sam Kulkarni on his company’s partnership with Vertex Pharma leading to breakthrough FDA approval for a sickle cell treatment, the first in US to be approved that uses CRISPR gene-editing technology.
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Major averages notched their third straight positive session. Wells Fargo’s Scott Wren and CFRA’s Sam Stovall break down the market action. Jefferies analyst Brent Thill breaks down Oracle’s revenue miss. Caruso Founder Rick Caruso talks rumors of a Macy’s sale and the broader state of commercial real estate. CRISPR Therapeutics CEO Sam Kulkarni on his company’s partnership with Vertex Pharma leading to breakthrough FDA approval for a sickle cell treatment, the first in US to be approved that uses CRISPR gene-editing technology.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.